wire - news in brief

« BACK

Life Sciences



Results 151 - 200 of 827.


Health - Life Sciences - 13.11.2017
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association Scientific Sessions 2017   The analysis showed a 31% reduction in cardiovascular death and a 31% reduction in all-cause mortality in patients whose inflammation - as measured by hsCRP - decreased below 2mg/L three months after initiating canakinumab

Health - Life Sciences - 13.11.2017
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
RTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD   AMG 334 has a robust data package, even in difficult to treat patients, and is on track to be the first CGRP to market for treatment of patients with chronic or episodic migraine   Cosentyx has strong differentiation based on its unique biology, which has been proven to

Health - Life Sciences - 10.11.2017
Use of antibiotics - only if necessary
Bern, 10.11.2017 - Spearheading the fight against antimicrobial resistance, the World Health Organization (WHO) launched its Antibiotic Awareness Week.

Health - Life Sciences - 08.11.2017
Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer MONALEESA-7 met primary e

Health - Life Sciences - 07.11.2017
FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation
FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease Approval based on data from a basket study, which enrolls participants across multiple diseases based predominantly on genetic profile Roche announced today that the US Food and Drug Administration (FDA) has approved Zelboraf (vemurafenib) for Erdheim-Chester disease (ECD) with BRAF V600 mutation.

Health - Life Sciences - 06.11.2017
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL Applica

Life Sciences - Health - 03.11.2017
Reading our brain chemistry
Reading our brain chemistry
Researchers at EPFL†have developed a new device and analysis method that let doctors measure the neurochemicals in a patient's brain. The† Microsystems Laboratory 4 (LMIS4)'s†system involves collecting microdroplets of cerebral fluid and analyzing them to obtain chemical data that can help doctors diagnose and treat neurodegenerative diseases.

Environment - Life Sciences - 03.11.2017
Mapping Functional Diversity of Forests with Remote Sensing
Mapping Functional Diversity of Forests with Remote Sensing
Ecological studies have demonstrated positive relationships between plant diversity and ecosystem functioning. Forests with higher functional diversity are generally more productive and stable over long timescales than less diverse forests. Diverse plant communities show increased resource use efficiency and utilization, enhanced ecosystem productivity and stability and can better cope with changing environmental conditions - an insurance effect of biodiversity.

Life Sciences - Environment - 02.11.2017
UZH Anthropologists Describe Third Orangutan Species
Two species of Indonesian orangutans had previously been officially described and recognized - the Pongo abelii , living on the island of Sumatra, and the Pongo pygmeaeus , endemic to Borneo. In 1997, researchers at the Australian National University discovered an isolated population of orangutans in Batang Toru, a region within the three Tapanuli districts in North Sumatra.

Life Sciences - Health - 02.11.2017
How Caries-Causing Bacteria Can Survive in Dental Plaque
How Caries-Causing Bacteria Can Survive in Dental Plaque
Extracellular polysaccharides play a central role in the survival capabilities of caries-causing bacteria in dental plaque, report researchers from the University of Basel's Preventative Dentistry and Oral Microbiology Clinic and Department of Biomedical Engineering in the journal Plos One. Cariogenic bacteria live in biofilm and attack dental enamel by converting sugar and starch into acids that dissolve out calcium from the enamel.

Health - Life Sciences - 02.11.2017
Novartis and Amgen announce expanded collaboration with Banner Alzheimer’s Institute in pioneering prevention program
Parties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD)   Clinical trial is part of the Generation Program, which includes cognitively healthy people at genetic risk of developing AD   Generation Study 2 aims to include a broader high-risk population, as compared to the ongoing Generation Study 1        44 million people globally are e

Health - Life Sciences - 01.11.2017
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
Primary results of pivotal Kymriah TM Phase II JULIET study in relapsed/refractory DLBCL † Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to first sickl

Health - Life Sciences - 31.10.2017
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy Submission based on updated

Life Sciences - Health - 30.10.2017
Important Mechanism of Epigenetic Gene Regulation Identified
DNA contains the blueprint of an entire organism. Based on the information in this blueprint, every cell knows what it must become and what function it must perform. Throughout the entire lifespan of an organism, the genetic information has to be read correctly to ensure that genes are active at the right time and in the right cells.

Health - Life Sciences - 28.10.2017
Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya vs. interferon beta-1a
PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs.

Life Sciences - 27.10.2017
Advanced artificial limbs mapped in the brain
Advanced artificial limbs mapped in the brain
EPFL scientists from the Center for Neuroprosthetics have used functional MRI to show how the brain re-maps motor and sensory pathways following targeted motor and sensory reinnervation (TMSR), a neuroprosthetic approach where residual limb nerves are rerouted towards intact muscles and skin regions to control a robotic limb.

Health - Life Sciences - 26.10.2017
Bacteria Have a Sense of Touch
Bacteria Have a Sense of Touch
Although bacteria have no sensory organs in the classical sense, they are still masters in perceiving their environment. A research group at the University of Basel's Biozentrum has now discovered that bacteria not only respond to chemical signals, but also possess a sense of touch. In their recent publication in "Science", the researchers demonstrate how bacteria recognize surfaces and respond to this mechanical stimulus within seconds.

Health - Life Sciences - 25.10.2017
Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
Full data from the pivotal Phase III PARADIGMS study of Gilenya (fingolimod) in pediatric MS will be presented for the first time † With 54 accepted abstracts, Novartis presence spans from new siponimod (BAF312) data in secondary progressive MS (SPMS) to innovative research on neurofilaments - a promising MS biomarker - Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at

Life Sciences - 24.10.2017
High-Speed Locomotion Neurons Found in the Brainstem
High-Speed Locomotion Neurons Found in the Brainstem
A clearly defined subpopulation of neurons in the brainstem is essential to execute locomotion at high speeds. Interestingly, these high-speed neurons are intermingled with others that can elicit immediate stopping. How defined groups of brainstem neurons can regulate important aspects of full motor programs, reports a study by researchers of the Biozentrum at the University of Basel and the Friedrich Miescher Institute for Biomedical Research (FMI).

Life Sciences - Electroengineering - 20.10.2017
Embark on a cognitive revolution at EPFL
Use your brainwaves to control the workings of a machine and contribute to science at EPFL ArtLab's next art-science exhibition, "Mental Work" from October 27 th - February 11 th , 2018.

Health - Life Sciences - 16.10.2017
Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS
Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS Largest body of OCREVUS data presented at a congress to

Physics - Life Sciences - 09.10.2017

Life Sciences - 05.10.2017

Physics - Life Sciences - 04.10.2017
Highlighting the significance of structural analysis of biomolecules
Highlighting the significance of structural analysis of biomolecules
The Nobel Prize in Chemistry 2017 has been awarded to Jacques Dubochet of Switzerland, U.S.-based German scientist Joachim Frank, and Richard Henderson of the United Kingdom for the development of structural analysis of single biological molecules by means of cryo-electron microscopy.

Life Sciences - Health - 03.10.2017
Clumps as temporary storage
Clumps as temporary storage
Researchers at ETH have discovered that the formation of protein aggregates in yeast cells is reversible. This casts new light on human diseases that can be attributed to certain protein aggregates. Protein aggregates have a bad reputation. A number of human diseases, especially those of the nervous system, such as Alzheimer's, Parkinson's, or amyotrophic lateral sclerosis (ALS), are due to the clumping of degenerate proteins in nerve cells, creating aggregates that the cells cannot dissolve.

Environment - Life Sciences - 29.09.2017
5 professors appointed
At its meeting of 28 September 2017, the ETH Board appointed 5 new professors upon application of ETH Zurich President Lino Guzzella.

Health - Life Sciences - 28.09.2017
Novartis and UC Berkeley collaborate to tackle ’undruggable’ disease targets
Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer   New Novartis-Berkeley Center for Proteomics and Ch

Life Sciences - Health - 25.09.2017
New regulator for liver regeneration
New regulator for liver regeneration
By performing large-scale proteomics analysis of liver proteins, ETH researchers have discovered a protein that is essential for liver regeneration. They have also figured out the mechanism of the protein's function. The liver is a wonderful thing: it's the only organ able to fully regenerate with no scar tissue formation, even after major injury.

Life Sciences - Mathematics - 24.09.2017
A brain-system that builds confidence in what we see, hear and touch
A brain-system that builds confidence in what we see, hear and touch
A series of experiments at EPFL provide conclusive evidence that the brain uses a single mechanism (supramodality) to estimate confidence in different senses such as audition, touch, or vision. The study is published in the Journal of Neuroscience. Behavioral scientists and psychologists use the term "metacognition" to describe our ability to access, report and regulate our own mental states: "thinking about thinking", "knowing about knowing" "being aware about being aware", are all higher-order cognitive skills that fit this category.

Health - Life Sciences - 22.09.2017
Roche receives European approval for Actemra /RoActemra in giant cell arteritis
Roche receives European approval for Actemra /RoActemra in giant cell arteritis Actemra/RoActemra is the first therapy approved for the treatment of giant cell arteritis (GCA) in Europe GCA can lead to blindness, aortic aneurysm or stroke if left untreated The approval was based on the outcome of the phase III GiACTA study Roche announced today that the European Commission (EC) has approved Actemra /RoActemra (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition.

Physics - Life Sciences - 20.09.2017
X-ray and neutron imaging for palaeontologists and archaeologists
The interior of fossils and artefacts that are hundreds, thousands and yes, sometimes millions of years old can be examined at two PSI research facilities. A conversation with Federica Marone and Eberhard Lehmann, who are opening a new view into the past with their methods. Ms. Marone, Mr. Lehmann  -  palaeontologists and archaeologists regularly come to you to look inside fossils and ancient objects with your non-destructive analysis methods.

Health - Life Sciences - 20.09.2017
Novartis drug Rydapt (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
Novartis drug Rydapt (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) Significant overall surviv

Chemistry - Life Sciences - 19.09.2017
Nanocapsules Enable Cell-Inspired Metabolic Reactions
Nanocapsules Enable Cell-Inspired Metabolic Reactions
Researchers at the University of Basel succeeded in developing capsules capable of producing the bio-molecule glucose-6-phosphate that plays an important role in metabolic processes. The researchers were able to produce the metabolite in conditions very similar to the biochemical reaction inside natural cells.

Health - Life Sciences - 16.09.2017
Novartis’ Xolair confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
OPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled † Should a treatment pause be necessary, data showed almost 90% of chronic spontaneous urticaria (CSU) patients - previously well controlled - regained effective symptom control within 12 weeks of re-treatment on Xolair † Previous studies have shown that inadequately controlled CSU has a major impact on sleep, social l

Health - Life Sciences - 14.09.2017
Increase of antibiotic resistance - Antibiotic Awareness Week highlights the risks
Bern, 14.09.2017 - The global fight against antibiotic resistance is ramping up. The World Health Organization has launched an Antibiotic Awareness Week, which will be running for the first time in Switzerland from 13 to 19 November 2017.

Health - Life Sciences - 14.09.2017
Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira * safety and efficacy profile Sandoz proposed biosimilar adalimumab is currently under review by the European Medicines Agency for the treatment of several immunological diseases Sandoz expects that approval of biosimilar adalimumab would further improve access to treatment for people living with immunological diseases Holzkirchen, Septem

Health - Life Sciences - 13.09.2017
Vessels that help cancers spread can also boost cancer immunotherapy
Vessels that help cancers spread can also boost cancer immunotherapy
Scientists from Switzerland and the US have shown that lymphatic vessels can enable both metastasis and T-cell invasion, opening new paths for cancer immunotherapy. Many cancers, such as melanoma, are known to metastasize and spread by expanding nearby lymphatic vessels. This process, lymphangiogenesis, also helps the tumor evade the patient's own immune system, and it would be expected that inhibiting lymphangiogenesis, could enhance the efficacy of cancer immunotherapies, which are only effective in a minority of patients.

Health - Life Sciences - 12.09.2017
Sandoz proposed biosimilar rituximab accepted for review by the FDA
Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis Sandoz believes the comprehensive data package submitted to the FDA for review confirms that our

Health - Life Sciences - 09.09.2017
Novartis presents new data at EURETINA 2017 confirming Lucentis efficacy and durability vs aflibercept
Interim results of the head-to-head RIVAL study confirm strong efficacy and comparable durability versus aflibercept in patients with nAMD † Five-year results from the Lucentis LUMINOUS study, the largest ever in retinal disease, demonstrate real-world efficacy and safety across five retinal diseases Novartis, the global leader in ophthalmology, today reported new data confirming Lucentis (ranibizumab) efficacy and durability in patients with nAMD at the 17 th EURETINA Congress in Barcelona, Spain (September 7-10, 2017).

Health - Life Sciences - 08.09.2017
Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress
Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress First data on new blood-based assay for measuring tumour mutational burden Two prospective studies underway to assess the potential of tumour mutational burden to predict response to certain cancer immunotherapies Roche announced today that the first data on a novel blood-based assay, co-developed with Foundation Medicine (NASDAQ: FMI), will be presented during the European Society for Medical Oncology (ESMO) Congress from 8-12 September 2017 in Madrid, Spain.

Health - Life Sciences - 07.09.2017
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies AMG 334 (erenumab) delivered consistent reductions in monthly migraine days for patients with chronic migraine and prior treatment failure, a population with significant unmet need   Dedicated cardiovascular safety study reaffirmed placebo-like tolerability of erenumab as seen consisten

Health - Life Sciences - 06.09.2017
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer ALUR study shows 85% reduction in risk of disease worsening or death versus chemotherapy in patients with advanced ALK-positive NSCLC who had progressed on chemotherapy and crizotinib Roche today announced results from the global phase III ALUR study showing that Alecensa significantly reduc

Health - Life Sciences - 05.09.2017
Tuberculosis Research Against "Super Resistant Bacteria"
To fall ill from tuberculosis remains a great danger. A research team led by cell biologist Sťbastien Gagneux at the Swiss Tropical and Public Health Institute (Swiss TPH) examines the antibiotic resistance mechanisms of Mycobacterium tuberculosis.

Health - Life Sciences - 05.09.2017
Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS
Phase III PARADIGMS study in pediatric MS met its primary endpoint, showing a significant reduction in relapses occur with fingolimod versus interferon beta-1a † There is a significant unmet need for safe and effective MS treatments for children and adolescents, for whom there are no specifically approved disease-modifying therapies † Children and adolescents living with MS†face physical and cognitive disability that severely limits their ability to go about daily activities, such as going to†school † † PARADIGMS is a first of its kind study in pediatric MS.

Life Sciences - Environment - 05.09.2017
Combating Japanese Beetles with Fungi
Zurich-Reckenholz, 05.09.2017 - In June of this year, the Japanese beetle (Popillia japonica) was detected for the first time in Switzerland, in the canton of Ticino. Considered to be a quarantine pest, it is subject to obligatory control. Agroscope researchers are testing whether this quarantine pest can be controlled with fungi that are effective against May and June beetles.

Life Sciences - 05.09.2017
First Detailed Decoding of Complex Finger Millet Genome
First Detailed Decoding of Complex Finger Millet Genome
For many poor farmers in India and Africa, finger millet is a major staple food. The crop species is not only a rich source of minerals like calcium, iron, magnesium and zinc, and it contains many vitamins and essential amino acids.

Physics - Life Sciences - 04.09.2017
Like a Revolving Door: How Shuttling Proteins Operate Nuclear Pores
Like a Revolving Door: How Shuttling Proteins Operate Nuclear Pores
Nuclear pore complexes are tiny channels where the exchange of substances between the cell nucleus and the cytoplasm takes place. Scientists at the University of Basel report on startling new research that might overturn established models of nuclear transport regulation. Their study published in the Journal of Cell Biology reveals how shuttling proteins known as importins control the function of nuclear pores - as opposed to the view that nuclear pores control the shuttling of importins.

Life Sciences - Art and Design - 31.08.2017
Artists Target Ibexes
Artists Target Ibexes
The video and sound installations, sculptures, and pictures on display at the exhibition aim to build new bridges between art and the natural sciences.

Health - Life Sciences - 30.08.2017
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice First-in-clas

Life Sciences - Health - 30.08.2017
UZH Life Sciences Fund Invests in First Spin-off
UZH Life Sciences Fund Invests in First Spin-off
CUTISS is a company with a vision: To use personalized skin grafts to heal people all over the world with skin defects, including burn victims.